@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix chebi: . @prefix go: . @prefix obo: . @prefix occursIn: . @prefix do: . @prefix species: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 occursIn: do:0060108, obo:CLO_0002140, species:9606; rdf:object go:0008283; rdf:predicate belv:decreases; rdf:subject chebi:50095; a rdf:Statement . sub:assertion rdfs:label "a(CHEBI:bucladesine) -| bp(GOBP:\"cell proliferation\")" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_3; pav:version "20131211" . sub:_2 prov:value "As previously described, Western blot analyses of Ki-67 show two bands at 345 and 395 kDa (Gerdes et al., 1991). Our results show that treatment with tolbutamide or dbcAMP promoted a decrease of about 40 and 60%, respectively in the expression of both isoforms of Ki-67 protein (Fig. 2)."; prov:wasQuotedFrom pubmed:16718685 . sub:_3 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:16718685; prov:wasDerivedFrom beldoc:, sub:_2 . } sub:pubinfo { this: dct:created "2014-07-03T14:33:00.713+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }